Navigation Links
ImaginAb, Inc. and Dainippon Seiki (DNS) Co., Ltd. Conclude Technology Development Agreement for Automated Chemistry Systems
Date:4/11/2011

LOS ANGELES and KYOTO, Japan, April 11, 2011 /PRNewswire/ -- ImaginAb, Inc. and Dainippon Seiki Co., Ltd. have concluded a technology agreement around the development of automated chemistry systems for fluorination of proteins and peptides for diagnostic imaging with positron emission tomography (PET).

"Over the past 18 months, our academic and pharma client base has dramatically increased and we have been developing and in-licensing novel fluorine chemistries to streamline labeling of proteins and peptides for targeted molecular imaging with PET," said Dr. Christian Behrenbruch, CEO of ImaginAb. "DNS has tremendous automation and instrumentation experience in the chemistry / radiochemistry domain and we are delighted to be working with such a dynamic and innovative organization to deliver new solutions to our customers."

Mr. Masayoshi Sugihara, President of DNS commented, "We have seen a significant increase in the interest level in novel peptides and biologics for diagnostic imaging and believe in the commercial importance of automated fluorine chemistry to drive this industry ahead. We are pleased to be collaborating with ImaginAb to develop high-throughput fluorination solutions that will be suitable for both pre-clinical and (eventually) clinical use."*

About ImaginAb

Founded in 2007 by UCLA Faculty (Drs. Robert Reiter, Anna Wu and Christian Behrenbruch), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

About DNS

Based in Kyoto, Japan, Dainippon Seiki (DNS) Co., Ltd. is an innovation leader in automation, robotics and high-precision instrumentation. DNS is a best-in-class provider of fully automated synthesis, diagnostic/inspection and robotic assembly systems with solutions for both life sciences/pharmaceutical and semiconductor industries. For more information about DNS, visit www.dnseiki.co.jp.

*The products and services described in this press release have not attained regulatory approval for clinical use in Japan or the USA.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Anna Wu

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImaginAb, Inc. and Eurogentec S.A. Collaborate to Produce Antibody Fragments in Pichia
2. ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration
3. Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
4. Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
5. Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma
6. Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
7. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
8. Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula
9. Independent Study Concludes Medicare Competitive Bidding Program for Durable Medical Equipment Could Negatively Affect Care Access, Quality, and Choice for Seniors and People with Disabilities
10. Mr. Jean-Pierre Garnier Concludes his Mission at the Pierre Fabre Company
11. arGEN-X Concludes EUR 12.5 Million Series A Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017 Clarius Mobile Health, ... handheld ultrasound scanners this week at the American ... (ACOG) in San Diego, CA ... "Clarius is the perfect tool for clinicians to ... rate, and evaluate pregnancy-related complications like ectopic pregnancy ...
(Date:5/4/2017)... , May 4, 2017   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... or the "Company"), today announced that the Company,s first ... close on Thursday, May 11, 2017, and that the ... at 1:30 p.m. PT that afternoon. Management will provide ...
(Date:5/3/2017)... 2017  West Pharmaceutical Services, Inc. (NYSE: WST), ... drug administration, announced today that Fran DeGrazio ... and Diane Paskiet , Director, Scientific Affairs, ... on West,s expertise in the areas of safety ... providing commentary on updated industry guidance. ...
Breaking Medicine Technology:
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Yisrayl ... a new publication this week that is focusing on the Peace Agreements being discussed ... his Middle East sprint in a race to try to speed up peace talks ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based ... of proceeds from its 14th Annual Clays for Kids fundraiser, to be held ... Bennett, Colorado. , As part of BluSky’s partnership with The Adoption Exchange, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the ... Jersey School District had left education officials with a number of critical issues to ... the flooring had to be accomplished with little or no disruption to class schedules. ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is ... York City. He is known for his distinguished expertise and experience in the diagnosis ... holds sub-specialty training in treating renovascular disease and aortic aneurysm . He is ...
Breaking Medicine News(10 mins):